Daily Roundup

RMD.ASX ALK.ASX FRS.ASX ALX.ASX CGS.ASX

Resmed is divesting its MatrixCare business to focus on higher-growth opportunities. The healthcare technology company has agreed to sell the software platform to Frazier Healthcare Partners for $490 million in cash. MatrixCare serves over 15,000 providers and will continue operating under Resmed until the deal closes in Q1 of fiscal 2027. The company plans to return the proceeds to shareholders through buybacks and other corporate purposes. Resmed will share its full fiscal 2027 outlook when it reports fourth quarter results on August 6, 2026.

Alkane Resources is delivering strong production numbers. The gold miner produced 42,491 ounces of gold equivalent in the latest quarter, bringing its year-to-date total to 168,337 oz AuEq—putting it squarely in the top half of its FY2026 guidance range of 160,000 to 175,000 ounces. The company's balance sheet is looking particularly robust, with cash, bullion, and listed investments reaching $454 million after a $104 million quarterly increase. Managing Director Nic Earner highlighted the solid production performance and strengthened financial position as the company heads toward the end of its fiscal year.

Two takeover offers are moving forward in the resources sector. Zenith Minerals' board has unanimously recommended that shareholders accept Forrestania Resources' off-market takeover offer, which provides a 4.4% premium to recent trading prices. Under the terms, Zenith shareholders would receive one new Forrestania share for every 4.3 Zenith shares held. The board sees the deal as a strategic win, offering exposure to a larger, more diversified gold company with improved liquidity prospects. Shareholders have until July 31, 2026 to accept. Meanwhile, Atlas Arteria's IFM takeover offer has officially closed, with Diamond Infraco 1 Pty Ltd (an IFM subsidiary) now holding 67.43% voting power. Debbie Goodin has been re-elected as Independent Non-executive Chair, while John Wigglesworth was appointed Interim Chair as the boards search for a permanent Independent Chair.

Cogstate is entering its new fiscal year with impressive momentum. The clinical trials software company executed a record $89.0 million in net sales contracts during FY26, more than doubling the prior year's $41.3 million. Heading into FY27, Cogstate has locked in $118.5 million in contracted future revenue—a 32% jump year-over-year. Of that, $48.3 million is expected to convert to revenue in the coming year, with Clinical Trials revenue alone projected to hit $46.1 million, up 58% from the prior year. The surge reflects growing demand for the company's services in clinical trial management.